QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
British Columbia, |
98-1360810 | |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) | |
420 Lexington Aven ue |
||
(Address of principal executive offices) |
(Zip Code) |
Large accelerated filer |
☐ |
Accelerated filer |
☐ | |||
Non-accelerated filer |
☒ |
Smaller reporting company |
||||
Emerging growth company |
Page No. |
||||||
PART I. FINANCIAL INFORMATION |
||||||
Item 1. |
4 |
|||||
4 |
||||||
5 |
||||||
6 |
||||||
7 |
||||||
8 |
||||||
Item 2. |
34 |
|||||
Item 3. |
43 |
|||||
Item 4. |
43 |
|||||
44 |
||||||
Item 1. |
44 |
|||||
Item 1A. |
45 |
|||||
Item 2. |
61 |
|||||
Item 3. |
61 |
|||||
Item 4. |
61 |
|||||
Item 5. |
61 |
|||||
Item 6. |
61 |
|||||
62 |
ITEM 1. |
FINANCIAL STATEMENTS |
June 30, |
December 31, |
|||||||
2022 |
2021 |
|||||||
(Revised) |
||||||||
Assets |
||||||||
Cash |
$ | $ | ||||||
Restricted cash |
||||||||
Accounts receivable, net of allowance for doubtful accounts of $ |
||||||||
Prepaid expenses |
||||||||
Inventories, net |
||||||||
Other current assets |
||||||||
|
|
|
|
|||||
Current Assets |
||||||||
Investments |
||||||||
Property, plant and equipment, net |
||||||||
Right-of-use |
||||||||
Other long-term assets |
||||||||
Intangible assets, net |
||||||||
|
|
|
|
|||||
Total Assets |
$ |
$ |
||||||
|
|
|
|
|||||
Liabilities and Shareholder’s Deficit |
||||||||
Accounts payable |
$ | $ | ||||||
Accrued and other current liabilities |
||||||||
Current portion of long-term debt, net of issuance costs |
||||||||
Derivative liabilities |
||||||||
Current portion of lease liabilities |
||||||||
|
|
|
|
|||||
Current Liabilities |
||||||||
Long-term debt, net of issuance costs |
||||||||
Deferred income tax |
||||||||
Long-term portion of lease liabilities |
||||||||
|
|
|
|
|||||
Total Liabilities |
||||||||
|
|
|
|
|||||
Commitments and Contingencies |
||||||||
Shareholders’ Equity (Deficit) |
||||||||
Common shares — d |
||||||||
Shares to be issued |
||||||||
Additional paid-in capital (Refer to Note 6) |
||||||||
Accumulated deficit |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Total Shareholders’ Equity (Deficit) |
$ |
$ |
( |
) | ||||
|
|
|
|
|||||
Total Liabilities and Shareholders’ Equity (Deficit) |
$ |
$ |
||||||
|
|
|
|
Three Months Ended June 30, |
Six Months Ended June 30, |
|||||||||||||||
2022 |
2021 |
2022 |
2021 |
|||||||||||||
Revenues, net of discounts |
$ |
$ |
$ |
$ |
||||||||||||
Costs and expenses applicable to revenues |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Gross profit |
||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Operating expenses |
||||||||||||||||
Selling, general and administrative expenses |
||||||||||||||||
Depreciation and amortization |
||||||||||||||||
Write-downs, recoveries and other charges, net |
( |
) | ||||||||||||||
Impairment loss |
||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total operating expenses |
||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
(Loss) Income from operations |
( |
) |
( |
) |
( |
) | ||||||||||
Interest income |
||||||||||||||||
Other income |
||||||||||||||||
Interest expense |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
Accretion expense |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
Provision for debt obligation fee |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
Loss on debt extinguishment (Refer to Note 5) |
( |
) | ( |
) | ||||||||||||
Losses from change in fair value of financial instruments |
( |
) | ( |
) | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Loss before income taxes |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||
Income tax expense |
||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Net loss |
$ |
( |
) |
$ |
( |
) |
$ |
( |
) |
$ |
( |
) | ||||
|
|
|
|
|
|
|
|
|||||||||
Net loss per share - basic and diluted |
$ |
( |
) |
$ |
( |
) |
$ |
( |
) |
$ |
( |
) | ||||
Weighted average number of common shares outstanding - basic and diluted |
Three Months Ended June 30, 2022 |
||||||||||||||||||||
Number of Common Shares (‘000) |
Shares to be Issued |
Additional Paid-in-Capital |
Accumulated Deficit |
Total Shareholders’ (Deficit) Equity |
||||||||||||||||
Balance – March 31, 2022 |
$ |
$ |
$ |
( |
) |
$ |
( |
) | ||||||||||||
Share-based compensation |
— | — | — | |||||||||||||||||
Share issuance - Recapitalization Transaction |
— | — | ||||||||||||||||||
Net loss |
— | — | — | ( |
) | ( |
) | |||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Balance – June 30, 2022 |
$ |
$ |
$ |
( |
) |
$ |
||||||||||||||
|
|
|
|
|
|
|
|
|
|
Six Months Ended June 30, 2022 |
||||||||||||||||||||
Number of Common Shares (‘000) |
Shares to be Issued |
Additional Paid-in-Capital |
Accumulated Deficit |
Total Shareholders’ (Deficit) Equity |
||||||||||||||||
Balance – January 1, 2022 - (Revised) |
$ |
$ |
$ |
( |
) |
$ |
( |
) | ||||||||||||
Share-based compensation |
— | — | — | |||||||||||||||||
Share issuance - Recapitalization Transaction |
— | — | ||||||||||||||||||
Net loss |
— | — | — | ( |
) | ( |
) | |||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Balance – June 30, 2022 |
$ |
$ |
$ |
( |
) |
$ |
||||||||||||||
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, 2021 |
||||||||||||||||||||
Number of Common Shares (‘000) |
Shares to be Issued |
Additional Paid-in-Capital |
Accumulated Deficit |
Total Shareholders’ Equity |
||||||||||||||||
Balance – March 31, 2021 |
$ |
$ |
$ |
( |
) |
$ |
||||||||||||||
Share-based compensation |
— | — | — | |||||||||||||||||
Net loss |
— | — | — | ( |
) | ( |
) | |||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Balance – June 30, 2021 |
$ |
$ |
$ |
( |
) |
$ |
||||||||||||||
|
|
|
|
|
|
|
|
|
|
Six Months Ended June 30, 2021 |
||||||||||||||||||||
Number of Common Shares (‘000) |
Shares to be Issued |
Additional Paid-in-Capital |
Accumulated Deficit |
Total Shareholders’ Equity |
||||||||||||||||
Balance – January 1, 2021 - (Revised) |
$ |
$ |
$ |
( |
) |
$ |
||||||||||||||
Share-based compensation |
— | — | — | |||||||||||||||||
Net loss |
— | — | — | ( |
) | ( |
) | |||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Balance – June 30, 2021 |
$ |
$ |
$ |
( |
) |
$ |
||||||||||||||
|
|
|
|
|
|
|
|
|
|
Six Months Ended June 30, |
||||||||
2022 |
2021 |
|||||||
CASH FLOW FROM OPERATING ACTIVITIES |
||||||||
Net loss |
$ |
( |
) | $ | ( |
) | ||
Adjustments to reconcile net loss to cash (used in) provided by operations: |
||||||||
Interest income |
( |
) | ( |
) | ||||
Interest expense |
||||||||
Accretion expense |
||||||||
Debt obligation fees |
||||||||
Impairment loss |
— | |||||||
Depreciation and amortization |
||||||||
Write-downs, recoveries and other charges, net |
||||||||
Share-based compensation |
||||||||
Losses from change in fair value of financial instruments |
( |
) | ||||||
Gain from nonmonetary consideration from acquisition (Refer to Note 4) |
( |
) | — | |||||
Loss on debt extinguishment (Refer to Note 5) |
— | |||||||
Change in operating assets and liabilities (Refer to Note 13) |
||||||||
|
|
|
|
|||||
NET CASH FLOW (USED IN) PROVIDED BY OPERATING ACTIVITIES |
$ |
( |
) |
$ |
||||
|
|
|
|
|||||
CASH FLOW FROM INVESTING ACTIVITIES |
||||||||
Purchase of property, plant and equipment |
( |
) | ( |
) | ||||
Acquisition of other intangible assets |
( |
) | ( |
) | ||||
Proceeds from sale of property, plant and equipment |
— | |||||||
Issuance of related party promissory note |
( |
) | ( |
) | ||||
Purchase of subsidiaries, net of cash acquired |
— | |||||||
|
|
|
|
|||||
NET CASH USED IN INVESTING ACTIVITIES |
$ |
( |
) |
$ |
( |
) | ||
|
|
|
|
|||||
CASH FLOW FROM FINANCING ACTIVITIES |
||||||||
Proceeds from issuance of debt |
||||||||
Debt issuance costs |
— | ( |
) | |||||
Repayment of debt |
( |
) | ( |
) | ||||
|
|
|
|
|||||
NET CASH PROVIDED BY FINANCING ACTIVITIES |
$ |
$ |
||||||
|
|
|
|
|||||
CASH AND RESTRICTED CASH: |
||||||||
NET INCREASE IN CASH AND RESTRICTED CASH DURING THE PERIOD |
||||||||
|
|
|
|
|||||
CASH AND RESTRICTED CASH, BEGINNING OF PERIOD (Refer to Note 13) |
||||||||
|
|
|
|
|||||
CASH AND RESTRICTED CASH, END OF PERIOD (Refer to Note 13) |
$ |
$ |
||||||
|
|
|
|
(a) |
Description of Business |
(b) |
Basis of Presentation |
(c) |
Consummation of Recapitalization Transaction |
(d) |
Going Concern |
(e) |
Basis of Consolidation |
(f) |
Use of Estimates |
(g) |
Change in Estimates |
(h) |
Coronavirus Pandemic |
(i) |
Reclassification |
Prior Year’s Line item |
Reclassified Amount |
Current Year’s Line item | ||||||||
Three Months Ended June 30, 2021 |
Six Months Ended June 30, 2021 |
|||||||||
Depreciation and amortization |
$ | $ | Selling, general and administrative expenses | |||||||
Depreciation and amortization |
( |
) | ( |
) | Depreciation and amortization |
(j) |
Revision of Prior Period Financial Statements |
December 31, 2021 |
||||||||||||
As previously reported |
Adjustment |
As adjusted |
||||||||||
Inventories |
$ | $ | ( |
) | $ | |||||||
Current assets |
( |
) | ||||||||||
Total assets |
( |
) | ||||||||||
Accrued and other current liabilities |
( |
) | ||||||||||
Current liabilities |
( |
) | ||||||||||
Total liabilities |
( |
) | ||||||||||
Accumulated deficit |
( |
) | ( |
) | ( |
) | ||||||
Total shareholders’ deficit |
( |
) | ( |
) | ( |
) | ||||||
Total liabilities and shareholders’ deficit |
( |
) |
Year Ended December 31, 2021 |
||||||||||||
As previously reported |
Adjustment |
As adjusted |
||||||||||
Costs and expenses applicable to revenues |
$ | ( |
) | $ | ( |
) | $ | ( |
) | |||
Gross profit |
( |
) | ||||||||||
Loss from operations |
( |
) | ( |
) | ( |
) | ||||||
Loss from operations before income tax |
( |
) | ( |
) | ( |
) | ||||||
Income tax expense |
( |
) | ||||||||||
Net loss |
( |
) | ( |
) | ( |
) | ||||||
Earnings per share |
( |
) | ( |
) | ( |
) |
June 30, 2022 |
||||||||||||
As reported |
Adjustment |
As adjusted |
||||||||||
Accumulated deficit – Balance January 1, 2022 |
$ | ( |
) | $ | ( |
) | $ | ( |
) | |||
Total Shareholders’ deficit – Balance January 1, 2022 |
( |
) | ( |
) | ( |
) |
Operating Leases |
||||
2023 |
$ | |||
2024 |
||||
2025 |
||||
2026 |
||||
2027 |
||||
Thereafter |
||||
|
|
|||
Total lease payments |
$ | |||
Less: interest expense |
( |
) | ||
|
|
|||
Present value of lease liabilities |
$ | |||
Weighted-average remaining lease term (years) |
||||
Weighted-average discount rate |
% | |||
|
|
Balance Sheet Information |
Classification |
June 30, 2022 |
December 31, 2021 |
|||||||
Right-of-use |
Operating leases | $ |
$ |
|||||||
|
|
|
|
|||||||
Lease l iabilities |
||||||||||
Current portion of lease liabilities |
Operating leases |
$ | $ | |||||||
Long-term lease liabilities |
Operating leases |
|||||||||
|
|
|
|
|||||||
Total |
$ |
$ |
||||||||
|
|
|
|
June 30, 2022 |
December 31, 2021 |
|||||||
(Revised) |
||||||||
Supplies |
$ | $ | ||||||
Raw materials |
||||||||
Work in process |
||||||||
Finished goods |
||||||||
|
|
|
|
|||||
Total |
$ |
$ |
||||||
|
|
|
|
Consideration |
||||
Cash |
$ | |||
Settlement of pre-existing relationships |
||||
|
|
|||
Fair value of consideration |
$ |
|||
|
|
|||
Assets acquired and liabilities assumed |
||||
Cash |
$ | |||
Fixed assets |
||||
Other non-current assets |
||||
Intangible assets |
||||
Accounts payable |
( |
) | ||
Accrued and other current liabilities |
( |
) | ||
|
|
|||
Net assets acquired |
$ |
|||
|
|
• | renegotiation of existing financing arrangements and other material contracts, including any amendments, waivers, extensions or similar agreements with the Lenders and/or stakeholders of the Company and/or its subsidiaries that the Special Committee determines are in the best interest of the Company and/or its subsidiaries; |
• | managing available sources of capital, including equity investments or debt financing or refinancing and the terms thereof; |
• | implementing the operational and financial restructuring of the Company and its subsidiaries and their respective businesses, assets and licensure and other rights; and |
• | implementing other potential strategic transactions. |
Secured Notes (1) |
March 2019 Debentures |
May 2019 Debentures |
June Secured Debentures |
Additional Secured Debentures |
June Unsecured Debentures |
Other |
Total |
|||||||||||||||||||||||||
As of January 1, 2022 |
$ |
$ |
$ |
$ |
$ |
$ |
||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
Fair value of financial liabilities issued |
— | — | ||||||||||||||||||||||||||||||
Accretion of balance |
— |
|||||||||||||||||||||||||||||||
Debt extinguishment |
( |
) | ( |
) | ( |
) | — | — | — | — | ( |
) | ||||||||||||||||||||
Repayment |
— | — | — | — | — | — | ( |
) | ( |
) | ||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
As of June 30, 2022 |
$ |
$ |
$ |
$ |
$ |
$ |
$ |
$ |
||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) | This amount includes the Company’s obligation to pay an exit fee of $ |
• | An aggregate of |
• | There were |
June 30, 2022 |
||||||||
Units |
Weighted Average Exercise Price (C$) |
|||||||
Warrants outstanding, beginning |
$ | |||||||
Granted |
||||||||
Forfeited |
( |
) | ||||||
Expired |
( |
) | ||||||
|
|
|
|
|||||
Warrants outstanding, ending |
$ |
|||||||
|
|
|
|
June 30, 2022 |
December 31, 2021 |
|||||||
Risk-free interest rate |
% | |||||||
Expected dividend yield |
% | |||||||
Expected volatility |
% | |||||||
Expected life |
June 30, 2022 |
December 31, 2021 |
|||||||||||||||
Year of expiration |
Number Outstanding |
Weighted Average Exercise Price (C$) |
Number Outstanding |
Weighted Average Exercise Price (C$) |
||||||||||||
2022 |
||||||||||||||||
2023 |
||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Warrants outstanding |
$ |
$ |
||||||||||||||
|
|
|
|
|
|
|
|
June 30, 2022 |
December 31, 2021 |
|||||||
Common share options |
||||||||
Restricted s tock units |
||||||||
Warrants |
||||||||
Secured notes |
||||||||
Debentures |
||||||||
MPX dilutive instruments (1) |
||||||||
|
|
|
|
|||||
Total |
||||||||
|
|
|
|
(1) |
Prior to the acquisition of MPX Bioceutical Corporation (“MPX”) on February 5, 2019 (the “MPX Acquisition”), MPX had instruments outstanding that were potentially dilutive and as a result of the MPX Acquisition, the Company assumed certain of these instruments. |
June 30, 2022 |
December 31, 2021 |
|||||||||||||||||||||||
Units |
Weighted Average Exercise Price (C$) |
Weighted Average Contractual Life |
Units |
Weighted Average Exercise Price (C$) |
Weighted Average Contractual Life |
|||||||||||||||||||
Options outstanding, beginning |
$ | — | $ | — | ||||||||||||||||||||
Granted |
— | — | ||||||||||||||||||||||
Exercised |
— | — | ||||||||||||||||||||||
Cancellations |
( |
) | — | — | ||||||||||||||||||||
Forfeitures |
( |
) | — | — | ||||||||||||||||||||
Expirations |
( |
) | — | ( |
) | — | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Options outstanding, ending |
$ |
— |
$ |
|||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
June 30, 2022 |
||||||||
Units |
Weighted Average Grant Price (C$) |
|||||||
Unvested balance, beginning |
$ | |||||||
Granted |
||||||||
Vested |
( |